---
figid: PMC9639785__fphar-13-979300-g008
pmcid: PMC9639785
image_filename: fphar-13-979300-g008.jpg
figure_link: /pmc/articles/PMC9639785/figure/F8/
number: FIGURE 8
figure_title: ''
caption: (A) Effect of ERK and JNK inhibitors on the heme oxhgenase-1. The heme oxhgenase-1(HO-1)
  concentrations (ng/ml) in rat aortic rings, express the presence physiological glucose
  concentration (11.1 mM, Control), 44 mM glucose (GLU), 44 mM glucose and 300 mM
  sulfasalazine (GLU + SSZ) 44 mM glucose, 300 mM sulfasalazine and 10 µM JNK inhibitor
  SP600125 GLU + SSZ + JNK-i), 44 mM glucose, 300 mM sulfasalazine, 10 µM ERK inhibitor
  U0126 (GLU + SSZ + ERK-i*), 44 mM glucose, 300 mM sulfasalazine, 10 µM ERK inhibitor
  U0126 and 10 µM JNK inhibitor SP600125 (GLU + SSZ + ERK-i + JNK-i). Bars indicate
  mean values ±SEM, from 9, 9, 5, 5, 5 and 5 aortic rings (Control, GLU, GLU + SSZ,
  GLU + SSZ + JNK-i. GLU + SSZ + ERK-i, GLU + SSZ + ERK-i + JNK-i). *p < 0.05 for
  larger concentration HO-1 in GLU + SSZ + ERK-i vs. GLU + SSZ and *p < 0.05 for smaller
  concentration GLU + SSZ + ERK-i + JNK-i vs. GLU + SSZ (Unpaired t test). (B) Effect
  of ERK and JNK inhibitors on total antioxidant capacity. The total antioxidant capacity
  (TAS) concentrations (ng/ml) in rat aortic rings, express the presence physiological
  glucose concentration (11.1 mM, Control), 44 mM glucose (GLU), 44 mM glucose and
  300 mM sulfasalazine (GLU + SSZ) 44 mM glucose, 300 mM sulfasalazine and 10 µM JNK
  inhibitor SP600125 GLU + SSZ + JNK-i), 44 mM glucose, 300 mM sulfasalazine, 10 µM
  ERK inhibitor U0126 (GLU + SSZ + ERK-i*), 44 mM glucose, 300 mM sulfasalazine, 10 µM
  ERK inhibitor U0126 and 10 µM JNK inhibitor SP600125 (GLU + SSZ + ERK-i + JNK-i).
  Bars indicate mean values ±SEM, from 12, 4, 5, 4, 5 and 6 aortic rings (Control,
  GLU, GLU + SSZ, GLU + SSZ + JNK-i. GLU + SSZ + ERK-i, GLU + SSZ + ERK-i + JNK-i).
  ***p < 0.001 for smaller concentration TAS in GLU + SSZ + ERK-i + JNK-i vs. GLU
  + SSZ (Unpaired t test). (C) Effect of ERK and JNK inhibitors on total oxidant capacity.
  The total antioxidant capacity (TOS) concentrations (ng/ml) in rat aortic rings,
  express the presence physiological glucose concentration (11.1 mM, Control), 44 mM
  glucose (GLU), 44 mM glucose and 300 mM sulfasalazine (GLU + SSZ) 44 mM glucose,
  300 mM sulfasalazine and 10 µM JNK inhibitor SP600125 GLU + SSZ + JNK-i), 44 mM
  glucose, 300 mM sulfasalazine, 10 µM ERK inhibitor U0126 (GLU + SSZ + ERK-i*), 44 mM
  glucose, 300 mM sulfasalazine, 10 µM ERK inhibitor U0126 and 10 µM JNK inhibitor
  SP600125 (GLU + SSZ + ERK-i + JNK-i). Bars indicate mean values ±SEM, from 12, 4,
  5, 4, 5 and 6 aortic rings (Control, GLU, GLU + SSZ, GLU + SSZ + JNK-i. GLU + SSZ
  + ERK-i, GLU + SSZ + ERK-i + JNK-i). *p < 0.05 for smaller concentration TOS in
  GLU + SSZ + ERK-i + JNK-i vs. GLU + SSZ *p < 0.05 for smaller concentration GLU
  + SSZ + ERK-i + JNK-i vs. GLU + SSZ (Unpaired t test). (D) Effect of ERK and JNK
  inhibitors on endothelial nitric oxide synthase. The endothelial nitric oxide synthase
  (eNOS) concentrations (ng/ml) in rat aortic rings, express the presence physiological
  glucose concentration (11.1 mM, Control), 44 mM glucose (GLU), 44 mM glucose and
  300 mM sulfasalazine (GLU + SSZ) 44 mM glucose, 300 mM sulfasalazine and 10 µM JNK
  inhibitor SP600125 GLU + SSZ + JNK-i), 44 mM glucose, 300 mM sulfasalazine, 10 µM
  ERK inhibitor U0126 (GLU + SSZ + ERK-i*), 44 mM glucose, 300 mM sulfasalazine, 10 µM
  ERK inhibitor U0126 and 10 µM JNK inhibitor SP600125 (GLU + SSZ + ERK-i + JNK-i).
  Bars indicate mean values ±SEM, from 12, 11, 5, 5, 5 and 5 aortic rings (Control,
  GLU, GLU + SSZ, GLU + SSZ + JNK-i. GLU + SSZ + ERK-i, GLU + SSZ + ERK-i + JNK-i).
article_title: Effect of sulfasalazine on endothelium-dependent vascular response
  by the activation of Nrf2 signalling pathway.
citation: Muhammed Ikbal Sonmez, et al. Front Pharmacol. 2022;13:979300.
year: '2022'

doi: 10.3389/fphar.2022.979300
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.

keywords:
- diabetes mellitus
- sulfasalazine
- Nrf2
- ERK
- rat aorta

---
